Obesity
Details of the Concept
Obesity is a chronic, multifactorial disease with complex biological, psychosocial, socioeconomic, and environmental determinants. WHO/AHA define overweight as BMI ≥25 and <30 kg/m², and obesity as BMI ≥30 kg/m². Asian-specific thresholds are lower (overweight ≥24, obesity ≥28 kg/m² in China). BMI has meaningful limitations: considerable variation by sex, age, and race/ethnicity means BMI alone cannot classify individual body fat or cardiometabolic risk. Waist circumference (WC) and visceral adiposity are independent CVD risk markers that complement BMI assessment.
Epidemiology
- 603.7 million adults globally had obesity in 2015; prevalence doubled between 1980 and 2015 in 73 countries. An estimated 39–49% of the world population has overweight or obesity. (sources/obesity-cv-aha-2021, rating: very high)
- US crude obesity prevalence: 39.8% in 2015–2016 (class 3 obesity [BMI ≥40]: 7.7%); racial/ethnic disparities range from 5.5% (non-Hispanic White men) to 16.9% (non-Hispanic Black women) in class 3 obesity. (sources/obesity-cv-aha-2021, rating: very high)
- High BMI contributed to 4.0 million deaths globally in 2015, more than two-thirds from cardiovascular disease. (sources/obesity-cv-aha-2021, rating: very high)
- Structural racism, weight stigmatization, socioeconomic inequality, and obesogenic environments drive racial/ethnic disparities in obesity prevalence in the US. (sources/obesity-cv-aha-2021, rating: very high)
Classification and Body Composition Measures
BMI Categories (WHO)
- Normal weight: BMI 18.5–24.9 kg/m²
- Overweight: BMI ≥25–29.9 kg/m²
- Class 1 obesity: BMI 30–34.9 kg/m²
- Class 2 obesity: BMI 35–39.9 kg/m²
- Class 3 obesity: BMI ≥40 kg/m²
Beyond BMI
- WC as a measure of abdominal obesity adds critical CVD risk information alongside BMI; high WC even at normal BMI ("normal-weight obesity") unmasks elevated CVD risk. (sources/obesity-cv-aha-2021, rating: very high)
- Waist-to-height ratio may be a better predictor of CVD than WC alone. Waist-to-hip ratio (WHR) predicts cardiovascular mortality independently of BMI. (sources/obesity-cv-aha-2021, rating: very high)
- Imaging (CT, MRI) quantifies visceral adipose tissue (VAT), subcutaneous fat, and ectopic fat depots with precision; see concepts/Visceral-Adiposity. (sources/obesity-cv-aha-2021, rating: very high)
- "Metabolically healthy obesity" (excess weight without excess VAT) may be a transient phenotype — the majority of individuals progress to metabolically unhealthy obesity over time. (sources/obesity-cv-aha-2021, rating: very high)
Cardiovascular Consequences
Coronary Artery Disease
- Obesity is a strong risk factor for incident CAD; meta-analysis of >300,000 adults demonstrated elevated CAD risk across overweight and obese BMI ranges. At each BMI level, higher WC/WHR confers additional CAD and cardiovascular mortality risk. (sources/obesity-cv-aha-2021, rating: very high)
- Cumulative exposure to excess adiposity (BMI-years, WC-years) is a stronger predictor of CAD than single-time-point measures. (sources/obesity-cv-aha-2021, rating: very high)
- Mechanisms: insulin resistance, dyslipidemia, endothelial dysfunction, systemic and vascular inflammation, LDL oxidation, ectopic fat (pericardial, epicardial) paracrine signaling. (sources/obesity-cv-aha-2021, rating: very high)
- Medical weight loss does not clearly reduce CAD rates in clinical trials; bariatric surgery reduces CAD risk in prospective studies (Swedish Obese Subjects [SOS] study). (sources/obesity-cv-aha-2021, rating: very high)
- See concepts/Obesity-Paradox for the BMI-CVD short-term outcome paradox.
Heart Failure
- HF incidence increases 5% (men) and 7% (women) per 1-unit BMI increase after adjustment for other risk factors. (sources/obesity-cv-aha-2021, rating: very high)
- HFpEF is more strongly associated with obesity than HFrEF: overweight → 38% higher HFpEF risk; class 1 obesity → 56% higher HFpEF risk (independently of CVD risk factors). (sources/obesity-cv-aha-2021, rating: very high)
- Obesity-HFpEF: distinct phenotype with greater concentric LV remodeling, RV dilatation, pericardial restraint, ventricular interdependence, and lower exercise capacity vs non-obese HFpEF. (sources/obesity-cv-aha-2021, rating: very high)
- BNP is lower in obesity (including in HF); normal BNP does not exclude HFpEF in obese patients. (sources/obesity-cv-aha-2021, rating: very high)
- See entities/Heart-Failure and entities/HFpEF.
Sudden Cardiac Death
- Every 5-unit BMI increment confers a 16% higher SCD risk. Obesity is the most common nonischaemic cause of SCD. (sources/obesity-cv-aha-2021, rating: very high)
- Mechanisms: LVH, QT prolongation, premature ventricular complexes, autonomic imbalance, QRS fragmentation, fibrosis, epicardial fat infiltration → reentrant circuits. (sources/obesity-cv-aha-2021, rating: very high)
- EAT-specific SCD mechanisms: EAT on ventricular free walls correlates with PVC frequency; paracardial + EAT sum positively related to VT/VF in HF patients. EAT infiltration → fibro-fatty deposits → re-entrant ventricular tachycardia circuits. Adipokine secretome (TNF-α, IL-1β) → Ito reduction and APD prolongation → repolarisation heterogeneity and Tpeak–Tend prolongation → SCD risk. (sources/epi-adipose-arrhythmia-jacc-2021, rating: high)
- Higher thoracic impedance impairs defibrillation success; body habitus compromises CPR quality. (sources/obesity-cv-aha-2021, rating: very high)
- See concepts/Sudden-Cardiac-Death and concepts/Epicardial-Adipose-Tissue-Arrhythmogenesis.
Atrial Fibrillation
- Obesity accounts for ~1/5 of AF cases; every 5-unit BMI increment → 29% greater incident AF risk. (sources/obesity-cv-aha-2021, rating: very high)
- BMI 30–34.9: 54% increased risk of AF progression from paroxysmal to permanent; class 2 obesity: 87% increase. (sources/obesity-cv-aha-2021, rating: very high)
- Epicardial adipose tissue infiltrates atrial myocardium → conduction block, voltage abnormalities, AF vulnerability; EAT-AF association is stronger than overall or abdominal obesity-AF association. Three mechanistic pathways: structural infiltration (zigzag conduction → re-entry), electrotonic Cx43 coupling (hypothetical), and paracrine secretome (adipokines → APD prolongation + fibrosis; EVs with profibrotic miRNA). See concepts/Epicardial-Adipose-Tissue-Arrhythmogenesis. (sources/epi-adipose-arrhythmia-jacc-2021, rating: high; sources/obesity-cv-aha-2021, rating: very high)
- Weight loss ≥10% confers a ~6-fold higher likelihood of freedom from AF at 5 years; weight loss is now considered the 4th pillar of AF management. (sources/obesity-cv-aha-2021, rating: very high)
- See entities/Atrial-Fibrillation and concepts/Visceral-Adiposity.
Weight Loss Interventions
Medical Weight Loss
- Lifestyle modification improves metabolic syndrome, inflammation, and endothelial dysfunction; modest medical weight loss (5–10 kg) does not clearly reduce CAD event rates in clinical trials (Look AHEAD). (sources/obesity-cv-aha-2021, rating: very high)
- Post hoc analysis of Look AHEAD: ≥10% body weight loss → significant reductions in CV events. (sources/obesity-cv-aha-2021, rating: very high)
- Mediterranean diet reduces MACE in high-risk patients. (sources/obesity-cv-aha-2021, rating: very high)
- Aerobic exercise reduces VAT even without weight loss (~6.1% reduction in meta-analysis). (sources/obesity-cv-aha-2021, rating: very high)
NuSH Pharmacotherapy (ACC 2025 Framework)
The ACC 2025 Expert Consensus Statement formalised a paradigm shift: cardiologists are now expected to prescribe NuSH therapies for eligible obese CVD patients without requiring a failed lifestyle intervention attempt first. (sources/weight-mx-acc-2025, rating: very high)
Weight loss thresholds for CV benefit:
- ≥5%: improved triglycerides, fasting glucose, systolic BP; incident disease prevention
- 10–15%: CVD risk reduction
-
15%: CV mortality reduction and HFpEF adverse outcome reduction (sources/weight-mx-acc-2025, rating: very high)
Eligibility for NuSH therapies: BMI ≥30 kg/m² OR BMI ≥27 kg/m² with a weight-related comorbidity; lifetime high BMI can be used. (sources/weight-mx-acc-2025, rating: very high)
Approved agents and CV outcome evidence:
- Liraglutide (Saxenda): SCALE trial weight ↓8.0%; LEADER CVOT (T2DM high CV risk, n=9,340): MACE HR 0.87 (95% CI 0.78–0.97) (sources/weight-mx-acc-2025, rating: very high)
- Semaglutide (Wegovy): STEP-1 trial weight ↓14.9%; SELECT (CVD + BMI >27 + no T2DM, n=17,604, 3.3yr): MACE HR 0.80 (95% CI 0.72–0.90); weight ↓9.1 kg; HF hospitalization HR 0.79 NS — first MACE benefit in obese CVD patients without diabetes; STEP-HFpEF: KCCQ +7.8 pts + weight ↓10.7 pp in HFpEF (sources/weight-mx-acc-2025, rating: very high; sources/semaglutide-stephfpef-nejm-2023, rating: very high)
- Tirzepatide (Zepbound): SURMOUNT-1 weight ↓20.9%; SUMMIT (HFpEF + obesity, n=731, 104 wk): CV death/worsening HF HR 0.62 (P=0.026) — first hard composite outcome benefit in obesity-HFpEF (sources/weight-mx-acc-2025, rating: very high; sources/tirzepatide-hfpef-summit-nejm-2025, rating: very high)
Practical points: Compounded NuSH therapies are strongly discouraged. De-escalate antihypertensives and diuretics as weight falls. Long-term continuation is the default plan. See concepts/NuSH-Therapies for full prescribing framework.
Older Pharmacological Data
- GLP-1 agonists (liraglutide 1.8 mg) reduce MACE and CV death in T2DM (LEADER trial). (sources/obesity-cv-aha-2021, rating: very high)
- SGLT2 inhibitors (dapagliflozin) reduce worsening HF or CV death in overweight/obese HFrEF regardless of diabetes. (sources/obesity-cv-aha-2021, rating: very high)
Bariatric Surgery
- SOS study: significantly lower fatal and nonfatal CV events in bariatric surgery vs non-surgical controls (non-randomized prospective). (sources/obesity-cv-aha-2021, rating: very high)
- Retrospective study (n=20,235): lower macrovascular disease incidence (mainly lower CAD) with bariatric surgery. (sources/obesity-cv-aha-2021, rating: very high)
- Weight loss with surgery (10–40 kg) vs medical weight loss (5–10 kg) likely explains the different CVD outcome results. (sources/obesity-cv-aha-2021, rating: very high)
- Class 3 obesity is a relative contraindication for heart transplantation; not universally considered a contraindication for LVAD. (sources/obesity-cv-aha-2021, rating: very high)
Contradictions / Open Questions
- Obesity paradox in CVD: Overweight/class 1 obesity confers better short-term CVD outcomes, but the mechanism is unclear. Proposed explanations include lead time bias, cardiorespiratory fitness confounding, and a "lean paradox" (low reserve against cardiac cachexia). The paradox wanes at class 3 obesity. (sources/obesity-cv-aha-2021, rating: very high)
- SELECT confirms intentional pharmacologic weight loss reverses the obesity paradox: Semaglutide 2.4 mg in CVD patients (no T2DM, BMI >27) reduced MACE HR 0.80 despite weight loss only ↓9.1 kg — confirming that pharmacologic weight loss in CVD patients is beneficial, not harmful. This directly contradicts observational "obesity paradox" data. (sources/weight-mx-acc-2025, rating: very high)
- CAD risk mediation by traditional risk factors: ~50% of the obesity–CAD association is explained by hypertension, dyslipidemia, and glucose intolerance, but the residual independent risk remains debated. (sources/obesity-cv-aha-2021, rating: very high)
- Medical vs surgical weight loss and CVD: No randomized controlled trial exists comparing bariatric surgery with optimal medical therapy for MACE as the primary endpoint. (sources/obesity-cv-aha-2021, rating: very high)
- Tirzepatide MACE data outside HFpEF pending: SELECT established semaglutide MACE benefit in non-T2DM CVD patients. Tirzepatide MACE data in non-HFpEF CVD patients without T2DM are awaited from SURMOUNT-MMO (n=15,374; estimated completion 2027). (sources/weight-mx-acc-2025, rating: very high)
Connections
- Related to concepts/NuSH-Therapies — preferred pharmacotherapy framework for obesity-CVD; ACC 2025 CCG
- Related to concepts/GLP-1-Receptor-Agonists — drug class; LEADER/SUSTAIN-6/SELECT CVOT data
- Related to entities/Semaglutide — SELECT MACE benefit in CVD + obesity without T2DM; STEP-HFpEF
- Related to entities/Tirzepatide — SUMMIT HFpEF composite benefit; greatest weight loss of available agents
- Related to concepts/Visceral-Adiposity — VAT and ectopic fat as CVD risk mechanisms
- Related to concepts/Obesity-Paradox — SELECT/SUMMIT data undermine observational paradox for intentional weight loss
- Related to entities/HFpEF — obesity as dominant HFpEF phenotype driver
- Related to entities/Heart-Failure — obesity as major HF risk factor; de-escalate diuretics on NuSH
- Related to entities/Atrial-Fibrillation — obesity-AF epidemiology and epicardial fat mechanism
- Related to concepts/Sudden-Cardiac-Death — obesity as most common nonischaemic SCD cause
- Related to concepts/Dyslipidemia-Management — metabolic syndrome overlap
- Related to entities/Hypertension — obesity-related RAAS/SNS activation
- Related to concepts/Epicardial-Adipose-Tissue-Arrhythmogenesis — EAT arrhythmogenic mechanisms (structural, electrotonic, paracrine)
- Related to sources/epi-adipose-arrhythmia-jacc-2021 — JACC 2021 EAT state-of-the-art review